Body composition and metabolic syndrome in patients with primary gout in Vietnam

Rheumatology

Volumn 49, Issue 12, 2010, Pages 2400-2407

  Dao, Hanh Hung ^a,b   Harun Or rashid, Md ^a   Sakamoto, Junichi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Bach Mai University Hospital   (Viet Nam)

Author keywords

Body composition; Diabetes; Dual energy X ray absorptiometry; Dyslipidaemia; Gout; Hypertension; Insulin resistance; Metabolic syndrome; Obesity; Vietnam

Indexed keywords

CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; BLOOD ANALYSIS; BODY COMPOSITION; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; GLUCOSE BLOOD LEVEL; GOUT; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; TRUNK; URIC ACID BLOOD LEVEL; VIET NAM; WAIST CIRCUMFERENCE;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; BODY COMPOSITION; BODY MASS INDEX; CASE-CONTROL STUDIES; DIET; GOUT; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RISK FACTORS; VIETNAM; YOUNG ADULT;

EID: 78649267491     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq274     Document Type: Article

References (50)

1. Doherty M. New insights into the epidemiology of gout. Rheumatology 2009;48:ii2-8.
2. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499-516.
3. Terkeltaub R, Zelman D, Scavulli J, Perez-Ruiz F, Lioté F. Gout Study Group: update on hyperuricemia and gout. Joint Bone Spine 2009;76:444-6.
4. Takahashi S, Yamamoto T, Moriwaki Z, Tsutsumi Z, Higashino K. Impaired lipoprotein metabolism in patients with primary gout: influence of alcohol intake and body weight. Br J Rheumatol 1994;33:731-4.
5. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis 1998;57:509-10.
6. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology 2008;47:1567-70.
7. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
8. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112: 2735-52.
9. Ford ES. Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 2005;28:1769-78.
10. Yoo HG, Lee SI, Chae HJ, Park SJ, Lee YC, Yoo WH. Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis. Rheumatol Int. Advance access published December 20, 2009, doi 10.1007/s00296-009-1304x.
11. Vazquez-Mellado J, Garcia CG, Vazquez SG et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol 2004;10:105-9.
12. Rho YH, Choi SJ, Lee YH et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005;20:1029-33.
13. Chen SY, Chen CL, Shen ML. Manifestation of metabolic syndrome associated with male gout in different age strata. Clin Rheumatol 2007;26:1453-7.
14. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007;57:109-15.
15. Inokuchi T, Tsutsumi Z, Takahashi S, Ka T, Moriwaki Y, Yamamoto T. Increased frequency of metabolic syndrome and its individual metabolic abnormalities in Japanese patients with primary gout. J Clin Rheumatol 2010;16: 109-12.
16. Kuo CF, See LC, Luo SF et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology 2010;49:141-6.
17. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988;41:237-42.
18. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
19. Choi HK, Curhan G. Independent impact of gout on mortality for coronary heart disease. Circulation 2007;116: 894-900.
20. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
21. Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the management of gout. Rheumatology 2007;46:1372-4.
22. Roddy E, Mallen CD, Hider SL, Jordan KP. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology 2010;49:105-11.
23. Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis 2007;1269-70.
24. Steering Committee of the WHO Western Pacific Region, IASO & IOTF. The Asia-Pacific perspective: redefining obesity and its treatment. IASO & IOTF, Australia: Steering Committee of the WHO Western Pacific Region, 2000.
25. Deurenberg P, Yap M, van Staversen WA. Body mass index and percent body fat: a meta-analysis among different ethnic groups. Int J Obes 1998;22:1164-71.
26. Wang J, Thornton JC, Bari S et al. Comparisons of waist circumferences measured at 4 sites. Am J Clin Nutr 2003; 77:379-84.
27. Pietrobelli A, Heymsfiel SB. Establishing body composition in obesity. J Endocrinol Invest 2002;25: 884-92.
28. Kohrt WM. Preliminary evidence that DEXA provides an accurate assessment of body composition. J Appl Physiol 1998;84:372-7.
29. Glickmann SG, Marn CS, Supiano MA, Dengel DR. Validity and reliability of dual energy X-ray absorptiometry for the assessment of abdominal adiposity. J Appl Physiol 2004; 97:509-14.
30. Kamel EG, McNeill G, Han TS et al. Measurement of abdominal fat by magnetic resonance imaging, dual-energy X-ray absorptiometry and anthropometry in non-obese men and women. Int J Obes 1999;23:686-92.
31. Ito H, Nakasuga K, Ohshima A et al. Detection of cardiovascular risk factors by indices of obesity obtained from anthropometry and dual energy X ray absorptiometry in Japanese individuals. Int J Obes 2003;27:232-7.
32. Boorsma W, Snijder MB, Nijpels G et al. Body composition, insulin sensitivity, and cardiovascular disease profile in healthy Europeans. Obesity 2008;16: 2696-701.
33. Lee K, Lee S, Kim YJ, Kim YJ. Waist circumference, dual-energy X-ray absorptiometrically measured abdominal adiposity, and computed tomographically derived intra-abdominal fat area on detecting metabolic risk factors in obese women. Nutrition 2008;24: 625-31.
34. Khan NC, Khoi HH. Double burden of malnutrition: the Vietnamese perspective. Asia Pac J Clin Nutr 2008; 17(Suppl. 1):116-8.
35. Giay T, Khoi HH. Use of body mass index in the assessment of adult nutritional status in Vietnam. Eur J Clin Nutr 1994;48:S124-30.
36. Minh Hoa TT, Darmawan J, Chen SL, Van Hung N, Thi Nhi C, Ngoc An T. Prevalence of the rheumatic diseases in urban Vietnam: a WHO-ILAR COPCORD study. J Rheumatol 2003;30:2252-6.
37. Son le NT, Kunii D, Hung NTK, Sakai T, Yamamoto S. The metabolic syndrome: prevalence and risk factors in the urban population of Ho Chi Minh City. Diabetes Res Clin Pract 2005;67:243-50.
38. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20: 895-900.
39. HOLOGIC Explorer. Operator's Manual and User's guide. Waltham, MA: Hologic Inc., 2005.
40. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54.
41. NCEP Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
42. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-62.
43. Takahashi S, Moriwaki Y, Tsutsumi Z, Yamakita J, Yamamoto T, Hada T. Increased visceral fat accumulation further aggravates the risk of insulin resistance in gout. Metabolism 2001;50:393-8.
44. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
45. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary artery risk development in young adults. Ann Epidemiol 1998;8: 250-61.
46. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008-11.
47. Puig JG, Martinez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008;20: 187-91.
48. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007;120: 442-7.
49. Janssen I, Heymsfiel SB, Allison DB, Kotler DP, Ross R. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr 2002;75: 683-8.
50. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.